Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms.
Neuroendocrine tumours (NETs) represent a heterogeneous family of neoplasms, which may develop from different endocrine glands (such as the pituitary, the parathyroid or the neuroendocrine adrenal glands), endocrine islets (within the thyroid or pancreas) as well as from endocrine cells dispersed be...
Principais autores: | Grozinsky-Glasberg, S, Shimon, I, Korbonits, M, Grossman, AB |
---|---|
Formato: | Journal article |
Idioma: | English |
Publicado em: |
2008
|
Registros relacionados
-
The role of somatostatin analogues in the treatment of neuroendocrine tumours.
por: Grozinsky-Glasberg, S, et al.
Publicado em: (2008) -
Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues.
por: Kaltsas, G, et al.
Publicado em: (2005) -
Imaging neuroendocrine tumours with radiolabelled somatostatin analogues and X-ray computed tomography: a comparative study.
por: King, C, et al.
Publicado em: (1993) -
Are serotonin metabolite levels related to bone mineral density in patients with neuroendocrine tumours?
por: Gupta, P, et al.
Publicado em: (2014) -
Localization of neuroendocrine tumours and insulinomas using radiolabelled somatostatin analogues, 123I-Tyr3-octreotide and 111In-pentatreotide.
por: Ur, E, et al.
Publicado em: (1993)